Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Metrics to compare | SPRL | Peers Peers - average of corresponding metrics from companies closely matching SPRL: SMSPHARMA, MOREPENLAB, AHCL, ANUHPHR, ALIVUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRLPeersSector |
|---|---|---|---|---|
P/E Ratio | 33.9x | 35.6x | −0.6x | |
PEG Ratio | 2.09 | 0.79 | 0.00 | |
Price/Book | 5.7x | 3.5x | 2.6x | |
Price / LTM Sales | 8.6x | 3.8x | 3.3x | |
Upside (Analyst Target) | 11.0% | 11.8% | 40.4% | |
Fair Value Upside | Unlock | 6.5% | 4.4% | Unlock |